GlobalCell-free protein expressionMarket Overview
According to Bergers Consulting, the global cell-free protein expression market size will be 2$7.6 billion, growing at a CAGR of 6. 2023-202896%。
Important factors for the growth of the cell-free protein expression market include increasing R&D in proteomics and genomics, high prevalence of cancer and infectious diseases, and shorter expression times and structural adjustments. Cell-free protein expression utilizes cell lysates to produce the desired recombinant protein, and the main advantage of this technique is that it avoids workflow hurdles in maintaining cell culture or live cells. Cell lysates are produced by the breakdown and use of cellular components of eukaryotic or bacterial cells, and several cell-free protein expression systems based on E. coli, rabbit reticulocytes, wheat germ, human cell lines, and insect cells are currently available.
North America dominates the market
North America holds a major share of the cell-free protein expression market and is expected to continue to do so during the ** period with no significant fluctuations. The major factors behind the huge market size include the increasing prevalence of chronic diseases such as cancer, aging population, growing demand for targeted and personalized medicines, presence of major R&D facilities, and favorable initiatives in the United States. In the U.S. academic and biotechnology industries, cell-based research is on the rise. In recent years, initiatives have complemented the growth of the U.S. cell-free protein expression market. In the North American region, the United States holds the largest market share due to factors such as the increasing burden of cancer cases, which is expected to stimulate the demand for the cell-free protein expression market.
Cell-free protein expression marketDynamic
January 2022 Merck KGAA to about 7$800 million acquisition of Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO).
January 2022, Thermo Fisher Scientific IncTake about 18$500 million** acquisition of Peprotech. With this acquisition, Peprotech's portfolio of recombinant proteins will complement Thermo Fisher's cell culture media offerings and further enable Thermo Fisher to deliver significant benefits to its customers through integrated products.
Thermo Fisher Scientific is one of the major players in the cell-free protein expression market with a market share of 2156% market share. thermo fisher scientific, inc.Production of scientific instruments, consumables and chemicals, providing analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals and supplies to pharmaceutical and biotechnology companies, hospitals and clinical diagnostic laboratories, universities, research institutes and ** institutions.